Network News
Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]
read more
Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?
Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]
read more
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, 2026 — VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven computational partner for modern […]
read more
VectorBuilder Advances Free VectorBee Software to Help Researchers Work with Greater Control and Flexibility
Major VectorBee update reflects VectorBuilder’s continued investment in free, researcher-first tools for genetic engineering and vector design. CHICAGO — July 14, 2026 — VectorBuilder, a global leader in gene delivery technologies, is launching a major update to VectorBee, its acclaimed 100% free DNA software created to help researchers view, edit, annotate, and analyze DNA and protein sequences with […]
read more
Beyond Cell Painting: From Phenotypic Screening To Mechanistic Understanding Using Antibody Panels
In the past decade, collaboration between the imaging community and biopharma discovery teams has led to methodologies and workflows that increase the capability, throughput, and automation of cellular imaging and analysis pipelines. Unlike hypothesis-driven approaches or conventional screening assays focused on narrow research questions and a few molecular targets, morphological profiling explores broader biological questions […]
read more
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]
read more
VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering
The next-generation platform integrates VectorBuilder’s regulatory-compliant gene delivery technology with MaxCyte’s clinically validated electroporation platform to enable robust, scalable, and reliable clinical-grade cell engineering. Chicago, IL & Rockville, MD – June 23, 2026 – VectorBuilder, a global leader in gene delivery technologies and CDMO services, and MaxCyte, a leading, cell-engineering company providing enabling platform technologies to […]
read more
LEEI-Platform eFIT is Available to Industry and Research
KyooBe Tech is making its innovative vaccine development platform available to industry and research partners:Enabling faster and scalable vaccine production using Low-Energy Electron Irradiation (LEEI). Flexible Vaccine Manufacturing for Emerging Infectious Diseases Recent infectious disease events—from hantavirus outbreaks and meningitis cases to recurring disease outbreaks in livestock farming—highlight the need for flexibly scalable vaccine manufacturing […]
read more
Dr. Felix Kommoss awarded the 2026 Rudolf Virchow Prize
For his research on the development of rare malignant tumors in the hereditary DICER1 tumor predisposition syndrome, Dr. Felix Kommoss has been awarded the Rudolf Virchow Prize of the German Society of Pathology (Deutsche Gesellschaft für Pathologie, DGP) – the most prestigious research award in the field of pathology in Germany. Dr. Kommoss conducts research […]
read more
